The first cardiocel patches IMO were the key products to the companies long term prospects and therefore an absolutely crucial one to get right from launch.
As far as I can deduce (now), the patch failure rate problem went on for months and months prior to the eventual release of the problem to the market.
My guess is over 6 months? ?? longer??
Certainly from the time manufacturing was started until around mid late 2016?
Please correct me if this impression is incorrect.
q 1/ How long actually had the failures gone on for?
q 2/ Are shareholders seriously supposed to believe senior management, indeed the BOD at the time, had no idea about this problem with the companies key product, from the time it first started until it was eventually released to the market?
What are the facts?
Thank you
The first cardiocel patches IMO were the key products to the...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.25 |
Change
-0.500(2.20%) |
Mkt cap ! $427.4M | |||
| Open | High | Low | Value | Volume |
| $22.76 | $23.07 | $22.25 | $53.92K | 2.369K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243 | $22.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.68 | 682 | 2 |
View Market Depth
| Last trade - 10.44am 29/04/2024 (20 minute delay) ? |
| AVR (ASX) Chart |